Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The interaction between tumor cells and the local milieu where are homing has recently become the focus of extensive research in a broad range of malignancies. Among them, multiple myeloma (MM) is now recognized as a prototypical tumor model for the characterization of these interactions. This is due not only to the propensity of MM cells to target the skeleton and form lytic bone lesions, but because interactions of MM cells with normal cells of the bone milieu can attenuate the anti‐tumor activity of conventional therapies, such as glucocorticoids and standard cytotoxic agents, including alkylators. Herein, we highlight the recent advances in our understanding of cellular and molecular mechanisms of interactions between MM cells and their milieu. Particular emphasis is placed on the interface between MM cells and normal cell compartments of the BM, especially bone marrow stromal cells (BMSCs), and on the development of a series of new classes of therapeutic agents, including the proteasome inhibitor bortezomib, thalidomide and lenalidomide, which counteract specific aspects of those MM–BM interactions. The significant clinical activity of these novel therapies has not only led to a new era in the therapeutic management of this disease, but also underscored the importance of comprehensively characterizing the role of the local microenvironment in the pathophysiology of human neoplasias. J. Cell. Biochem. 101: 950–968, 2007. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“…bortezomib, thalidomide, and lenalidomide are clinically active in the treatment of not only MM patients with relapsed/refractory disease [Singhal et al., 1999; Richardson et al., 2002, 2003, 2005], but also in the newly diagnosed setting [Rajkumar et al., 2002, 2005, 2006; Weber et al., 2003].”
BackgroundSelf-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 2×
“Indeed, bortezomib, thalidomide, and lenalidomide are clinically active in the treatment of not only MM patients with relapsed/refractory disease [Singhal et al., 1999; Richardson et al., 2002, 2003, 2005], but also in the newly diagnosed setting [Rajkumar et al.”
BackgroundSelf-citationThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“…HGF, DKK-1; soluble forms of their respective receptors; as well as small-molecule inhibitors of downstream signaling cascades can inhibit tumor-associated neovascularization, tumor cell proliferation, and bone resorption, respectively [Holash et al., 2002; Tian et al., 2003; Hov et al., 2004].”
BackgroundAutocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · cited 1×
“…bortezomib, thalidomide, and lenalidomide are clinically active in the treatment of not only MM patients with relapsed/refractory disease [Singhal et al., 1999; Richardson et al., 2002, 2003, 2005], but also in the newly diagnosed setting [Rajkumar et al., 2002, 2005, 2006; Weber et al., 2003].”
BackgroundMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804 · cited 1×
“…bortezomib, thalidomide, and lenalidomide are clinically active in the treatment of not only MM patients with relapsed/refractory disease [Singhal et al., 1999; Richardson et al., 2002, 2003, 2005], but also in the newly diagnosed setting [Rajkumar et al., 2002, 2005, 2006; Weber et al., 2003].”
BackgroundSelf-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512 · cited 1×
“…bortezomib, thalidomide, and lenalidomide are clinically active in the treatment of not only MM patients with relapsed/refractory disease [Singhal et al., 1999; Richardson et al., 2002, 2003, 2005], but also in the newly diagnosed setting [Rajkumar et al., 2002, 2005, 2006; Weber et al., 2003].”
BackgroundBiologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 11×
“…et al., 1996; Mitsiades et al., 2004b], triggers proliferative/anti-apoptotic signaling cascades in MM cells, including PI-3K/Akt/mTOR/ p70S6K [Hideshima et al., 2001b; Mitsiades et al., 2004b]; IKK-a/NF-kB [Hideshima et al., 2002; Mitsiades et al., 2004b]; Ras/Raf/MAPK [Mitsiades et al.,…”
BackgroundInfluentialSelf-citationYaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207170 · Cited by 164 · cited 2×
“…for MM such as thalidomide, lenalidomide, and the proteasome inhibitor bortezomib, can overcome the protective effects of BMSCs onMM cells [Hideshima et al., 2000b, 2003], which may explain the clinical activity of these agents can exhibit even in steroid- and/or chemo-refractory MM…”
BackgroundSelf-citationRANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.
Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125 · cited 2×
“[Roux et al., 2002]; suppress osteoprotegerin (OPG), an endogenous antagonist of RANKL activity [Lacey et al.”
Background
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3096 · Cited by 539
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Metadata
- Authors
- Mitsiades, C. S., Mitsiades, N. S., Richardson, P. G., Munshi, N. C., & Anderson, K. C.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2007-06
- Volume
- 101
- Issue
- 4
- Pages
- 950-968
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2017456279
- Cited by
- 87
- References
- 17
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.